Founded in 1989, OrbiMed is a New York-based healthcare-dedicated investment firm managing approximately $5 billion in assets. It invests across the spectrum of healthcare companies, from private start-ups to large multinational corporations, focusing on biopharmaceuticals, life sciences, digital health, medical devices, and diagnostics sectors globally.

RA Capital Management is a Boston-based investment firm that specializes in life sciences and healthcare companies. The firm provides investment management and venture capital services, backing companies developing drugs, medical devices, diagnostics, and biotech tools. Its team combines expertise in biology, chemistry, and medicine with industry and business development experience. RA Capital supports companies across multiple stages, from seed funding to growth financings, including private and public rounds, and often takes board seats and seeks co-investment opportunities. Through its activity, it aims to identify technologies with potential to advance prevention and treatment, genetic testing and personalized medicine, and other patient-focused innovations.

Eli Lilly and Company is a global pharmaceutical leader engaged in the discovery, development, manufacture, and sale of medicines. It operates facilities in the United States, Puerto Rico, and many other countries, with products sold in about 135 countries. The company focuses on therapies in neuroscience, cardiometabolic, cancer, and immunology, and also conducts research in animal health and animal agriculture. Lilly supports patient outcomes and education through a philanthropic foundation that funds programs in underserved communities, including STEM education in Indianapolis.

Novo Holdings is a Danish holding and investment firm managing the assets of the Novo Nordisk Foundation. Established in 1999, it invests globally in life science companies at all stages of development, with a portfolio also including equities, bonds, real estate, and infrastructure.

New Enterprise Associates is a U.S.-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across stages and geographies, supporting startups from seed to growth. The firm operates globally with investments in the United States, Asia, and Brazil among others, and has a long track record of portfolio IPOs and acquisitions. It has over $19 billion in cumulative committed capital.

Samsara BioCapital is a Palo Alto-based venture capital firm founded in 2016 that focuses on the healthcare sector, including biotechnology, pharmaceuticals, oncology, and life sciences. The firm seeks opportunities in the United States and provides investment advisory services as part of its activities, supporting companies developing innovative therapies and related technologies.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore, and a global arm through Qiming Venture Partners USA. It manages multiple funds and invests in early and growth-stage companies across technology, information technology, healthcare, new consumer sectors, AI, robotics, semiconductors, software and digital health. The firm emphasizes a hands-on approach, often taking board seats and providing operational guidance to help CEOs scale and reach exits. Through its investments, it has backed hundreds of companies and supported numerous IPOs and M&A outcomes, with unicorns among its portfolio, illustrating breadth and depth across China and international markets.

Morningside is a venture capital firm that funds companies with novel science and technology. It pursues a long-term, value-building approach and emphasizes ethical conduct. Based in the greater Boston area, the firm has experienced professionals with backgrounds across life sciences, digital health, artificial intelligence, materials and technology. Established in 1986 as a family office for the Chan family, Morningside has supported education, research and healthcare through charitable commitments to institutions such as the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

Vivo Capital is a global healthcare investment firm based in Palo Alto with offices in Asia. Founded in 1996, it focuses on investing in and building high-quality companies in the United States and China. The firm engages across multiple strategies, including growth equity, private equity (buyouts), venture capital, and public equity, and invests in biopharmaceuticals, medical devices, and healthcare services. With about 25 years of operation, it manages approximately 5.8 billion in assets and has participated in over 290 public and private companies worldwide. The team comprises physicians, scientists, entrepreneurs, operating executives, and industry experts, reflecting a hands-on approach to helping portfolio companies scale in major healthcare markets.

Venrock is a Palo Alto-based venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on seed and early-stage investments in technology and healthcare, with interests spanning information technology, life sciences and related sectors in the United States. The firm has supported a broad portfolio of companies, including Apple, Intel, Illumina, DoubleClick, Athenahealth, Gilead Sciences, Nest, SlideShare and Tudou. Venrock emphasizes long-term partnerships with entrepreneurs, combining hands-on venture support with rigorous data analysis to help startups grow into enduring companies.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and based in San Francisco, with offices in Canada, the United States, and Europe. The firm invests across the healthcare sector at all stages of company development, with emphasis on discovery and development of novel therapeutics. It leverages deep investment, operating, and scientific expertise to take a hands-on approach to building companies. Since its inception, more than 65 portfolio companies have achieved successful acquisitions or IPOs, reflecting its track record of helping startups advance therapies, devices, and life sciences ventures. The firm focuses on medical devices, biotechnology, pharmaceuticals, and life sciences, including oncology. It aims to support early-stage and growth-stage companies across the United States, Canada, and Europe, enabling development across the healthcare continuum.

Deerfield Management is a New York-based investment firm established in 1994 that focuses on healthcare. It operates across investment, information, and philanthropy to support the healthcare ecosystem. The firm provides private and public investments and offers long-term, structured capital to both public and private healthcare companies. Its portfolio spans life sciences, medical devices, diagnostics, digital health, and health services. As an investment adviser, it seeks opportunities in healthcare products and services and aims to accelerate innovation by combining capital with industry insight.

Founded in 1986, ARCH Venture Partners is a venture capital firm specializing in investments that bring innovations in life sciences to market. It focuses on companies co-founded by scientists and entrepreneurs, with a strong track record in commercializing technologies from academic research institutions and national laboratories.

Established in 2020, the European Innovation Council supports innovative startups and researchers with promising ideas, focusing on early-stage companies with positive environmental, social, or governance impacts. It co-invests alongside private investors.

Redmile Group is a San Francisco-based private equity firm with an office in New York that focuses on investments in the healthcare sector, pursuing opportunities across venture, growth, and crossover stages to support healthcare companies with strategic capital and partnerships.

Pfizer is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines across a broad range of therapeutic areas. It maintains an extensive portfolio of prescription drugs and vaccines, with notable products such as Prevnar 13, Ibrance, and Eliquis. The company serves customers worldwide, with substantial international and emerging-market sales. Through ongoing research and development, Pfizer pursues new treatments to address major diseases, including cancer and neurodegenerative conditions, and aims to improve patient outcomes by delivering safe, effective, and accessible therapies. Founded in 1849 and headquartered in the United States, Pfizer operates globally to advance health care through science, partnerships, and scalable manufacturing capabilities.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

Logos Capital is a hedge fund manager based in San Francisco, founded in 2019, specializing in fundamental biotechnology investments. The firm combines in-house data analytics with scientific and clinical expertise to rigorously evaluate potential therapies and treatment platforms. It uses fundamental and sector-focused equity strategies and applies statistical modeling of clinical data to strengthen diligence and identify compelling opportunities with the aim of delivering uncorrelated returns. By integrating medical, scientific, and statistical perspectives, Logos Capital seeks to deepen its conviction in investment ideas and maintain disciplined risk management.

Deep Track Capital is a venture capital investment firm focused on life sciences and biotechnology, headquartered in Greenwich, Connecticut. Founded in 2020, the firm partners with management teams of innovative public and pre-IPO biotechnology companies, providing capital, time, expertise, and an extensive network to support growth. It seeks to lead transactions, build large syndicates, and participate in rounds led by other qualified investors, aiming to create value through strategic guidance and collaborative partnerships rather than simple financing.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. Founded in 2012, the company operates as an investment adviser and venture investor, seeking to identify and support innovative therapeutic solutions with the potential to improve patient outcomes. It provides investment services to pooled vehicles and participates in biotech investments across private and public markets, reflecting a commitment to advancing medical research.

Polaris Partners is a venture capital firm based in Boston, Massachusetts, with offices in San Francisco. Founded in 1996, it targets investments in technology and life science companies across the United States and Europe, supporting startups from early formation to profitable growth. The firm's healthcare and biotechnology focus encompasses digital health, consumer-centric care delivery, patient-provider solutions, data science and analytics, as well as therapeutics, genomics and other life science platforms. It backs companies across business-to-business and business-to-consumer models, software as a service, healthcare information technology and health tech sectors, partnering with repeat entrepreneurs to build durable, scale-ready businesses.

Atlas Venture is an early-stage venture capital firm based in Cambridge, Massachusetts, specializing in life sciences and biotechnology. It supports the translation of high-impact scientific discoveries into medicines for patients through a seed-led venture creation strategy that identifies and builds scalable companies with strong scientific foundations. The firm combines experienced scientists and career venture capitalists to select compelling opportunities and realize value, emphasizing early-stage investments in life sciences and technology. Atlas Venture also maintains a multi-disciplinary team able to advance startups from concept to clinical development and commercial viability.

HBM Healthcare Investments is a Switzerland-based investment firm founded in 2001 and based in Zug. It concentrates on the healthcare sector, spanning human medicine, biotechnology, medical technology and diagnostics. The firm maintains a diversified portfolio that includes private companies, public companies, funds, cash and other assets, reflecting exposure across different stages and sectors within healthcare.

Omega Funds is a Boston-based venture capital and private equity firm founded in 2004 that concentrates on early-stage investments in healthcare and biotech across North America and Western Europe, backing companies in life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service.

Founded in Paris in 1972, Sofinnova Partners is a venture capital firm dedicated to life sciences investments. With over €2 billion under management, the firm actively partners with entrepreneurs from seed to later-stage, focusing on biopharmaceuticals, medical devices, and industrial biotechnology. Sofinnova proactively sources deals, often leading Round A financings, and plays an active role in portfolio companies until exit.

Hercules Capital is a specialty finance company that provides senior secured loans and growth capital to privately held venture capital-backed companies across various stages of development in technology, life sciences, and sustainable and renewable technology industries. With over a decade of experience, Hercules offers innovative financing solutions tailored to each company's capital structure and business objectives.

Kurma Partners is a Paris-based investment management company focused on funding innovation in healthcare and biotechnology across Europe. Established in 2009, it targets early-stage to development capital for life sciences companies and digital health ventures, spanning healthcare, biotechnology, and related technology sectors. The firm pursues a hands-on approach to support research-driven startups, leveraging connections with research institutes and hospitals to advance therapeutic and medical innovations. Through its activity as a private equity and venture investor, Kurma Partners seeks to back companies throughout their growth trajectory, from initial concept to market readiness, helping them navigate clinical development, regulatory pathways, and commercialization in the European market.

SR One is the corporate venture capital arm of GlaxoSmithKline, investing globally in early-stage life science companies pursuing innovative science with the potential to significantly improve medical care. Since 1985, SR One has invested about $800 million in more than 180 companies.

Boxer Capital is the venture capital arm of Tavistock Group, based in San Diego, California. It invests in public and private biotechnology and life sciences companies across the drug development lifecycle, from early preclinical discovery to late-stage clinical and commercial assets. Founded in 2005, Boxer Capital focuses on biotechnology drug development opportunities.

SOSV is a global venture capital firm that supports early-stage startups through active, founder-first development programs. Its flagship initiatives HAX and IndieBio provide facilities, engineering resources, services, and laboratory equipment to accelerate product development and prepare companies for subsequent funding rounds. SOSV focuses on deep technology across health, environmental, and cross-border software sectors, aiming to solve human and planetary health challenges. In addition to providing capital, the firm emphasizes intensive programmatic support to help portfolio companies move quickly from seed toward growth, including customer acquisition and scale. The firm operates globally with a bias toward startups targeting rapid international expansion, especially in Asia, and tends to back a small cohort of high-potential companies to accelerate their progress and attract leading investors.

MPM Capital is a healthcare investment firm that finances biotechnology, life sciences, and medical technologies with the aim of translating science into clinical outcomes. The firm backs companies across stages from seed through late venture and growth, including oncology, medical devices, specialty pharma, and diagnostics, with investments typically spanning global opportunities in the United States, Europe, and Asia. It often serves as a lead investor and may take interim operating roles to support portfolio companies, leveraging a three-decade track record in building biotechnology and healthcare companies.

Casdin Capital is a New York-based investment firm focused on life sciences and healthcare. Founded in 2012 by Eli Casdin, the firm pursues private investments and research-driven opportunities across early- to late-stage companies in these sectors and is described as a venture capital firm and a registered investment adviser.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, with emphasis on drug discovery and development. It backs early-stage and seed companies in the United States, aiming to build science-driven businesses capable of delivering multiple product opportunities rather than short-term exits. The firm concentrates on oncology and other disease areas including inflammation, infectious disease, metabolic and cardiovascular disorders, and nervous system conditions, seeking to support platform-based discoveries with potential for significant therapeutic impact.

Canaan Partners is a San Francisco-based venture capital firm founded in 1987 that operates globally with offices in Israel and India. It focuses on early-stage investments in technology and healthcare, including software, fintech, enterprise/cloud, marketplaces, digital health, biopharma, and medtech, and it has a history of backing startups that achieve exits.

Founded in 2020, TCG Crossover is a venture capital firm dedicated to advancing disruptive medicines and supporting companies focused on improving patient lives. Based in Palo Alto with an additional office in New York City, the firm invests in both private and public biotechnology companies led by exceptional entrepreneurs.

Forbion is a venture capital firm based in Naarden, Netherlands, established in 2006. It specializes in early-stage investments within the life sciences and MedTech sectors, focusing on companies involved in drug development and addressing critical medical needs. The firm has a team of nine investment professionals and has built a strong track record since the late 1990s, with successful investments in various notable companies. Forbion manages assets exceeding €400 million across three active funds and co-manages BioGeneration Ventures, which targets academic spin-outs and seed investments in the Netherlands. The firm continues to play a significant role in advancing innovative healthcare solutions through its strategic investments.

F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, affiliated with Fidelity Investments. It backs technology and life sciences entrepreneurs across the Americas, Europe, and Asia, drawing on Fidelity’s experience in funding early-stage companies. The firm focuses on sectors such as healthcare IT, medtech, therapeutics, fintech, frontier technologies, crypto, and broader information technology and technology-enabled services. With a global network of regional teams and affiliated funds, F-Prime provides domain expertise, strategic guidance, and industry connections to help founders build durable companies. It operates with a long-term, founder-centric approach, emphasizing value creation rather than external fundraising pressures.

Founded in 2000, Aisling Capital is a New York-based investment firm focusing on mid-market and growth-oriented investments in life sciences, healthcare, and technology companies across the United States and Western Europe. The company aims to support leading global healthcare companies commercializing new products driven by biotechnology advancements.

Merck & Co. is a global biopharmaceutical company based in New Jersey that discovers, develops, and markets medicines and vaccines to treat cancer, infectious diseases, autoimmune disorders, and other conditions. The company maintains a strong cancer portfolio anchored by an immuno-oncology therapy platform led by Keytruda and a growing vaccine business including Gardasil for human papillomavirus. Its research arm, Merck Research Laboratories, focuses on discovering and developing therapies for cancer and neurodegenerative diseases. Merck also markets animal health products. Through its science-driven approach, Merck aims to deliver innovative products and therapies that improve patient outcomes worldwide.

Longitude Capital is a California-based investment firm focused on venture growth in life sciences, including biotechnology and medical technology companies. Founded in 2006, it targets both privately held and publicly traded life science companies and pursues a balanced portfolio of clinical-stage and commercial-stage assets with the potential for value creation within three to five years. The firm identifies opportunities through its broad industry network and thematic research into emerging therapeutic areas or sub-sectors, and uses a range of investment structures including traditional venture capital, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity-linked instruments. It maintains offices in Menlo Park, Greenwich, and Boston and operates as a registered investment adviser.

VenBio Partners is a California-based venture capital firm focused on life sciences and healthcare, investing across the drug discovery spectrum from early to late stages in the United States. The firm tends to lead its investments, builds syndicates, and positions portfolio companies to meet potential acquisition partners from the outset. It concentrates on preparing companies in areas such as intellectual property, chemistry, manufacturing and controls (CMC), and clinical trial design and regulatory considerations to maximize impact. Supported by an experienced team, VenBio aims to form lasting relationships with leaders in the field and help portfolio companies advance meaningful therapies.

Frazier Management, L.L.C. is a private equity and venture capital firm established in 1991 and headquartered in Seattle, Washington, with additional offices in North America. The firm specializes in growth equity financing and engages in a variety of investment strategies, including incubation, expansion stage equity, and corporate divestitures. Frazier Management focuses primarily on the healthcare sector, actively investing in drug development, pharmaceutical services, medical devices, and healthcare information technology, among other areas. The firm seeks to support companies at various stages of development, from startups to established businesses, typically investing between $3 million and $100 million per transaction. Frazier prefers to take majority stakes and often acts as a lead investor, taking board seats in its portfolio companies. Its investment strategy emphasizes profitable companies with a strong EBITDA, particularly in the United States, Canada, and Europe, concentrating on key regions such as the Bay Area, San Diego, Seattle, Boston, and North Carolina.

5AM Ventures is a San Francisco-based venture capital firm founded in 2002 by John Diekman and Andrew Schwab, with an office in Boston. It concentrates on seed- and early-stage investments in life sciences, healthcare and technology-related companies, including digital health and health technology. Its portfolio comprises firms in biopharmaceuticals, biotechnology, medical technology and related research instruments.

Founded in 1994, the European Investment Fund operates as a venture capital and private equity firm specializing in incubation, direct, secondary indirect, and fund of funds investments. It focuses on disruptive early-stage technology enterprises and supports micro, small, and medium-sized enterprises across Europe, primarily at early stages. The fund invests between €0.25 million and €60 million per transaction, with a preference for investing €130 million into private equity and venture capital funds.

SV Health Investors is a United States‑headquartered healthcare and life sciences venture capital and growth equity firm. Formerly known as SV Life Sciences, it supports entrepreneurs who create breakthrough companies and treatments across biotech, medical devices, and healthcare services. With offices in Boston, San Francisco and London, the firm has over two billion dollars of capital under management across seven private healthcare funds and more than two decades of activity in the US and Europe.

Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. The firm backs entrepreneurs with venture assistance, strategic guidance, and capital, focusing on bold, early-stage technology companies. It invests across sectors including AI, climate and sustainability, enterprise software, consumer technologies, fintech, digital health, medtech and diagnostics, therapeutics, and frontier technologies. Based in Menlo Park, the firm manages several funds to support startups across stages, prioritizing ventures that address large markets and have potential for significant social and economic impact.

Takeda Ventures is a strategic investment arm of Takeda Pharmaceutical Company Limited, focusing on direct and fund-of-fund investments in healthcare and life sciences sectors. It specializes in seed to mid-stage investments, with a primary focus on therapeutics, regenerative medicines, RNA/DNA modulation, and innovative protein/peptide biologics. The firm invests globally but has a strong presence in the United States, Canada, and Europe.

Third Rock Ventures is a Boston-based venture capital firm focused on investing in life sciences and healthcare companies in the United States. It backs startups developing medicines, diagnostics, medical devices, and related technologies with high growth potential, often providing substantial initial capital and strategic collaborations to advance development. The firm takes an active role in portfolio companies, frequently leading investment rounds and sometimes assuming key management positions, and collaborates with larger pharmaceutical and biotechnology companies. Since its founding in 2007, Third Rock has supported firms across biotechnology, therapeutics, oncology, medical devices, and data-driven life sciences, aiming to bring transformational healthcare innovations to market. The firm operates primarily from Boston with additional presence in San Francisco.

Mission BioCapital is a life science venture capital firm that backs early‑stage biotechnology companies. Based in Cambridge, Massachusetts, the firm draws on a leadership team with a long history of investing in and launching numerous early‑stage life science ventures. It operates in regions with strong research, discovery, and venture capital ecosystems and is known for providing deep expertise and active support to its portfolio companies.